Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 12, 2019updated 23 Dec 2019 9:28am

Roche’s drug mitigates relapse risk in late-stage study for NMOSD

A Phase III clinical trial by Roche demonstrated favourable outcomes for its satralizumab drug as a monotherapy in patients with neuromyelitis optica spectrum disorder (NMOSD).

A Phase III clinical trial by Roche demonstrated favourable outcomes for its satralizumab drug as a monotherapy in patients with neuromyelitis optica spectrum disorder (NMOSD).

NMOSD is a rare central nervous system disorder characterised by pathogenic AQP4-IgG antibodies that cause inflammatory lesions in the brain, spinal cord and optic nerves.

Patients suffering from the disorder have severe and unpredictable relapses that result in neurological damage.

Satralizumab is designed to target IL-6 signalling, which is linked to the inflammation in NMOSD and believed to be the cause of damage and disability.

The Phase III trial, known as SAkuraStar, compared the safety and efficacy of a 120mg subcutaneous dose of the drug with placebo in a total of 95 patients aged 20-70. Treatment was given at weeks zero, two and four, followed by four-week intervals thereafter.

The trial’s primary endpoint was the time to first protocol-defined relapse (PDR) and secondary endpoints included the visual analogue scale (VAS) score to measure pain and functional assessment of chronic illness therapy (FACIT) fatigue score.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

According to the results, satralizumab led to a 55% decrease in the relapse risk versus placebo, while a 74% reduction was observed in a subgroup of participants who were seropositive for AQP4-IgG antibodies.

Roche noted that seropositive patients usually have a more severe course of the disease.

Of the overall population who received the company’s drug, 76.1% and 72.1% were relapse-free at 48 and 96 weeks, respectively, compared to 61.9% and 51.2% on placebo.

In the subgroup of AQP4-IgG seropositive subjects, the figures were 82.9% and 76.5% with satralizumab versus 55.4% and 41.1% with placebo.

The serious adverse events were found to be similar between the study groups, with a comparatively low infections rate in the satralizumab group.

Roche chief medical officer and global product development head Sandra Horning said: “We are encouraged by these results and look forward to working with regulators over the coming months to bring satralizumab to people living with NMOSD as soon as possible.”

The company added that satralizumab also yielded positive results in the previous Phase III SAkuraSky trial, which assessed the drug in combination with a baseline immunosuppressant therapy for NMOSD.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU